Kidney cancer affects a large and growing number of patients. This report from Bristol-Myers Squibb (BMS) sets out a number of areas where focus from policymakers is required to ensure kidney cancer patients receive the high-quality care that they deserve, no matter where they are being treated. If the UK is to improve patient outcomes and patient experience in kidney cancer, action must be taken at points throughout the patient pathway, from diagnosis and treatment to follow up care. Otherwise, UK patients will continue to be at a disadvantage compared to those from other comparable countries.
This report has been developed following extensive research on the kidney cancer patient experience, as well as diagnostic and treatment pathways in the UK. It brings together insights gained from a series of interviews and two roundtable meetings in Scotland and England with the patient group community and health professionals. KCSN were instrumental in providing information about the patient experience for this report.